文献速递头颈外科

MDASI-HN症状评分用于口咽癌幸存者舌下神经病变早期风险分层

MDASI-HN Symptom Profiling for Early-Risk Stratification of Hypoglossal Neuropathy in Survivors of Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该回顾性队列研究纳入1297例接受根治性治疗的口咽癌患者,分析6项MDASI-HN症状条目轨迹,构建MDASI-HN-NERVE评分。结果显示评分越高,舌下神经病变风险越高(HR 1.35,95%CI 1.18-1.54),基线阈值3.4和治疗后3-6个月阈值3.5可区分高低风险组。

要点

  • MDASI-HN-NERVE评分每增加1分,舌下神经病变风险增加35%。
  • 基线阈值3.4和疗后3-6个月阈值3.5可分层舌下神经病变风险。
  • 基线及疗后3-6个月MDASI言语/嗓音单项评分也可区分风险。

核心结论

  • MDASI-HN言语/嗓音症状和MDASI-HN-NERVE评分可能为舌下神经病变风险的早期检测和监测提供实用、以患者为中心的方法。

研究设计与样本

  • 回顾性分析前瞻性队列研究数据,纳入2015年3月至2023年12月在MD Anderson癌症中心接受根治性治疗的1297例口咽癌患者。
  • 患者在基线和定期随访时完成症状评估,随访长达5年,舌下神经病变状态基于结构化病历回顾确定的临床体征分类。

主要发现

  • 1297例参与者中女性141例(10.9%),男性1156例(89.1%),平均(SD)年龄65.9(9.2)岁。
  • 较高的MDASI-HN-NERVE评分与舌下神经病变风险增加相关(风险比1.35;95%CI 1.18-1.54)。
  • 基线最佳阈值3.4和治疗后3-6个月最佳阈值3.5可区分高风险与低风险组,两组无舌下神经病变生存率显著不同。
  • 基线和治疗后3-6个月的MDASI言语/嗓音单项评分也可区分潜伏性舌下神经病变风险。

关键数值与推荐

  • MDASI-HN-NERVE评分与舌下神经病变风险的HR为1.35(95%CI 1.18-1.54)。
  • 基线最佳阈值为3.4,治疗后3-6个月最佳阈值为3.5。
  • 分析纳入6项MDASI-HN条目:咀嚼/吞咽、呛咳、言语/嗓音、黏液、疲劳和口干。

临床怎么用

  • 在口咽癌幸存者随访中,可采用MDASI-HN言语/嗓音症状和MDASI-HN-NERVE评分进行舌下神经病变风险的早期检测和监测。
  • 基线MDASI-HN-NERVE评分≥3.4或治疗后3-6个月≥3.5提示高风险,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypoglossal (CN XII) neuropathy is a debilitating latent toxic effect in survivors of oropharyngeal cancer (OPC), which is often underdiagnosed due to its delayed onset and subtle early signs and symptoms. There is no established patient-reported outcome tool to aid early detection. OBJECTIVE: To evaluate selected MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) symptom items for predicting CN XII neuropathy risk and derive a composite symptom-based nerve score (MDASI-HN-NERVE) with an optimal threshold for early risk stratification. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis used data from a prospective cohort study of 1297 patients with OPC who were treated with curative intent at MD Anderson Cancer Center between March 2015 and December 2023. Eligible patients completed symptom assessments at baseline and regular follow-up intervals for up to 5 years. CN XII neuropathy status was classified based on documented clinical signs through a structured health record review. Data were analyzed in June 2025. MAIN OUTCOMES AND MEASURES: Symptom trajectories of 6 MDASI-HN items (chewing/swallowing, choking, speech/voice, mucus, fatigue, and dry mouth) were analyzed using spaghetti plots and piecewise linear mixed-effects models. A MDASI-HN-NERVE score was derived from these items to quantify CN XII neuropathy-associated symptom burden. Time-dependent Cox models and Kaplan-Meier analyses were used to assess the risk of developing CN XII neuropathy, and optimal cut-off values were identified. RESULTS: Of 1297 participants, 141 (10.9%) were female and 1156 (89.1%) were male; the mean (SD) age was 65.9 (9.2) years. Higher MDASI-HN-NERVE scores were associated with an increased risk of CN XII neuropathy (hazard ratio, 1.35; 95% CI, 1.18-1.54). An optimal threshold of 3.4 at baseline and 3.5 at 3 to 6 months posttreatment distinguished high-risk vs low-risk groups with significantly different CN XII neuropathy-free survival. Single-item MDASI speech/voice scores at baseline and 3 to 6 months also discriminated latent CN XII neuropathy risk. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that MDASI-HN speech/voice symptoms and the MDASI-HN-NERVE score may provide a practical, patient-centered approach to aid early detection and monitoring of CN XII neuropathy risk. These findings provide early evidence to support the clinical use of MDASI-HN-based surveillance in oropharyngeal cancer survivorship care.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Song W, Peterson CB, Sahli A, et al. MDASI-HN Symptom Profiling for Early-Risk Stratification of Hypoglossal Neuropathy in Survivors of Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42024413. doi:10.1001/jamaoto.2026.0518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。